KMT2A Inhibitors
1 drugsAbout KMT2A
KMT2A is a histone methyltransferase involved in regulating gene expression through chromatin modification. It plays a crucial role in hematopoiesis and development.
Currently, there is no genetic evidence available for KMT2A as a therapeutic target. However, its role in cancer development makes it an attractive target.
KMT2A is targeted by one approved drug, KOMZIFTI, a small molecule developed by KURA Oncology for oncology indications. KOMZIFTI was first approved in 2025.
Top KMT2A Drugs
KURA Oncology is the only company with an approved drug targeting KMT2A.
Low competition suggests a high barrier to entry or untapped market potential.
KMT2A Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets KMT2A, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs represents a whitespace opportunity.
KMT2A Clinical Trials 15 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on KMT2A. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 0 | 0 | 12 | - |
| Phase 2 | 2 | 0 | 0 | 2 | - |
| Phase 3 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
KMT2A Drug Approval Timeline (2025 - 2025)
The first drug targeting KMT2A was approved in 2025.
Recent approval indicates growing interest, but also early stage market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 7 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on KMT2A. A trial counts if an approved drug acting on KMT2A is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.